Equity research was always a subsidised product. Nobody paid for it directly; it was funded out of trading commissions, and it existed because it generated order flow in the names it covered. That arrangement quietly financed coverage of hundreds of companies too small to justify the analyst on their own economics.
The subsidy is gone. Commissions compressed toward zero, research budgets were unbundled and separately negotiated, and the analysts who remained were reallocated to the names that could pay for them. The result is a coverage distribution that looks nothing like the market it is supposed to describe.
What happens to a company nobody follows
The immediate effect is mechanical. Without published estimates there is no consensus, and without a consensus a company cannot beat or miss, which removes the event structure that generates institutional attention. Screens that require a minimum number of covering analysts exclude the name automatically, and a great deal of institutional capital is allocated through exactly such screens.
Liquidity thins in response, and thin liquidity is self-reinforcing. A fund that cannot build a position without moving the price, or exit one without a discount, applies a haircut for that difficulty before it evaluates the business at all. The company is now priced for its trading characteristics rather than its cash flows, and no operating performance fully corrects it.
Managements have drawn the obvious conclusion, and it is showing up in the decisions that matter. Boards weighing a sale against continued independence are comparing a strategic buyer's offer against a public valuation they no longer believe reflects the business, which resolves a great many of those debates in one direction. Others have simply left, concluding that the compliance cost of being public buys access to a market that is not looking.
That reasoning runs directly against the companies rushing through the narrow window back into public markets, and the two facts belong together: the enthusiasm is concentrated at the top of the size range, where coverage still exists, while the tier below it is drifting the other way.
The same gravitational pull explains part of the index concentration that risk committees have started treating as a live exposure. Passive flows follow the benchmark, the benchmark follows market capitalisation, and capitalisation compounds where attention already is. Coverage is one of the channels through which that self-reinforcement operates, and it is the least discussed.
Some substitution is happening. Issuer-paid research has expanded, with the conflict everyone recognises and prices in. Independent boutiques have taken parts of the field, funded by the institutions that still care. Retail attention has flowed into individual names in a way that occasionally produces coverage of a sort, though it arrives without an estimate revision or a model behind it, and the maturing retail investor base has been more willing to do the work than the caricature allows.
None of it reconstitutes what was lost, because what was lost was a subsidy rather than a skill. The analysts still exist. Nothing pays them to look down the size range.
For the companies living inside the discount, the practical response has been to stop waiting for coverage and to do the work themselves — publishing longer disclosures, holding investor days without a bank attached, and speaking to shareholders directly rather than through an intermediary who is no longer there. It is an admission that the infrastructure is not coming back, and the ones that have made it earliest have generally been rewarded, which is its own quiet indictment of what the research function was actually providing.
Topics marketspublic markets
